SOLICITATION NOTICE
B -- IN VIVO EFFICACY STUDY
- Notice Date
- 8/3/2017
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Child Health and Human Development, Contracts Management Branch, 6710B Rockledge Dr., Suite 1124, MSC7000, Bethesda, Maryland, 20892-7510, United States
- ZIP Code
- 20892-7510
- Solicitation Number
- NIH-NIDDK-17-222
- Archive Date
- 8/29/2017
- Point of Contact
- Amber Harris, Phone: 3014028778
- E-Mail Address
-
amber.harris@nih.gov
(amber.harris@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NIH-NIDDK-17-222 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2005-95. The North American Industry Classification (NAICS) Code is 541380 and the business size standard is $15.0. However, this solicitation is not set aside for small business. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intend to procure on a sole source basis with GOVERNMENT SCIENTIFIC SOURCE INC. of 12351 Sunrise Valley Drive, Reston, Virginia 20191 for the purchase of an in-vivo efficacy study. The National Institute of Digestive, Diabetes & Kidney Diseases's (NIDDK) is conducting an in vitro efficacy study. The objective is to see if the NIDDK's modernized A3 agonists protect the liver from NASH (nonalcoholic steatohepatitis) liver disease better than the older compounds currently in clinical trials. Can-Fite BioPharma is currently running phase two clinical trials on NIDDK LBC invented A3 agonists for treatment of NASH. LBC scientists have continued the research into these A3 agonist and have improved the affinity and potency creating drugs that are more targeted. The NIDDK wishes to have these new drugs tested with the proprietary STAMTM model of NASH/fibrosis. SMC Laboratories uses a patented procedure that will provide the NIDDK with the most complete results. The relevant clinical trials related to this type of drug discovery is: New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017- Data show Namodenoson both prevents and inhibits liver fibrosis- Namodenoson is to be evaluated in upcoming Phase II trial for the treatment of NAFLD/NASH. Testing will commence over several weeks and both Data and Tissue slides returned to NIH after all studies are completed. The study will be completed within one year of award. In the light of the NIDDK's ongoing studies, consistency and continuity of research goals requires the utilization of SMC Laboratories' patented procedure for the requisite testing services. The proposed contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under authority of the 41 U.S.C. 253(c) (1), FAR 6.302. Only one responsible source and no other supplies or services will satisfy agency requirements. The offeror must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items with its offer. The provisions of FAR Clause 52.212-1 Instructions to Offerors - Commercial Items; FAR Clause 52.212-2, Evaluation - Commercial Items; FAR Clause 52.212-4, Contract Terms and Conditions - Commercial Items; and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items - Deviation for Simplified Acquisitions applies to this acquisition. The offeror must include their Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.acquisition.gov/far/. Interested vendors capable of furnishing the government with the services specified in this synopsis should submit a copy of their quotation to the below address or via email to amber.harris@nih.gov. Offers must also be accompanied by descriptive literature, delivery timeframe, warranties and/or other information that demonstrates that the offer meets all of the foregoing requirements. Quotations will be due on or before August 14, 2017 by 10 am, EST. via email or postal mail. The quotation must reference "Solicitation number" NIH-NIDDK-17-222. Quotations sent by postal mail or other mailing services must be submitted to the following address: Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Room 1159A, Bethesda, MD 20817. Attention: Amber Harris, by the date and time mentioned above. Any questions must be sent via email to amber.harris@nih.gov and must include solicitation#NIH-NIDDK-17-222 in the subject line of email. Faxed copies/responses will not be accepted. PLEASE NOTE: In order to receive an award, contractor must be registered for "All Awards" and have a valid certification in the System for Award Management (SAM) database at http://www.sam.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NICHD/NIH-NIDDK-17-222/listing.html)
- Place of Performance
- Address: BETHESDA, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04611065-W 20170805/170803232306-e6f80b97550a6951fff4698066dac940 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |